Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.

ABSTRACT:

Background

BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.

Patients and methods

In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg tw

SUBMITTER: Queirolo P 

PROVIDER: S-EPMC5844757 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature